| 91.88 -1.37 (-1.47%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 111.18 | 1-year : | 129.86 |
| Resists | First : | 95.19 | Second : | 111.18 |
| Pivot price | 87.35  |
|||
| Supports | First : | 81.03 |
Second : | 72.29 |
| MAs | MA(5) : | 92.74 |
MA(20) : | 86.25 |
| MA(100) : | 54.84 |
MA(250) : | 63.04 |
|
| MACD | MACD : | 6.2  |
Signal : | 6.4 |
| %K %D | K(14,3) : | 86.6 |
D(3) : | 90.1 |
| RSI | RSI(14): 74.5 |
|||
| 52-week | High : | 95.19 | Low : | 28.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CORT ] has closed below upper band by 27.2%. Bollinger Bands are 57.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 93.31 - 93.78 | 93.78 - 94.16 |
| Low: | 88.95 - 89.44 | 89.44 - 89.84 |
| Close: | 91.15 - 91.93 | 91.93 - 92.57 |
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Sat, 11 Jul 2026
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup - ChartMill
Fri, 10 Jul 2026
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors - Seeking Alpha
Thu, 09 Jul 2026
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Wed, 08 Jul 2026
Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings - Stock Titan
Wed, 08 Jul 2026
Insider at Corcept (NASDAQ: CORT) sells shares after option exercise - Stock Titan
Tue, 07 Jul 2026
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 107 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 75.7 (%) |
| Shares Short | 8,570 (K) |
| Shares Short P.Month | 9,320 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.94 |
| Profit Margin | 6.1 % |
| Operating Margin | -30.1 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | 7.1 % |
| Qtrly Rev. Growth | 4.9 % |
| Gross Profit (p.s.) | 7.03 |
| Sales Per Share | 7.16 |
| EBITDA (p.s.) | -0.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 120 (M) |
| Levered Free Cash Flow | 116 (M) |
| PE Ratio | 262.51 |
| PEG Ratio | 0.8 |
| Price to Book value | 15.46 |
| Price to Sales | 12.82 |
| Price to Cash Flow | 81.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|